Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (51-60 of 528) with videos related to

Pageof 53
Sort By:
Iscience|July 6, 2023
Intrinsically disordered proteins and conformational noise: The hypothesis a decade laterPrakash Kulkarni, Ravi Salgia, Govindan Rangarajan
BMC Cancer|August 3, 2016
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgia
Reviews on Recent Clinical Trials|May 14, 2008
Review of clinic trials: agents targeting c-MetOyewale Abidoye, Nadh Murukurthy, Ravi Salgia
Thescientificworldjournal|September 7, 2004
Receptor tyrosine kinases and inhibitors in lung cancerEvan Pisick, Simha Jagadeesh, Ravi Salgia
Thescientificworldjournal|October 7, 2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLCMartin Sattler, Oyewale Abidoye, Ravi Salgia
Molecular Therapy Oncolytics|April 13, 2019
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1<sup>st</sup>-Line Treatment for Non-Small-Cell Lung CancerChongkai Wang, Prakash Kulkarni, Ravi Salgia
Expert Opinion on Drug Safety|February 10, 2015
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patientsAlana Dikopf, Kevin Wood, Ravi Salgia
Cold Spring Harbor Molecular Case Studies|December 18, 2020
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring <i>MET</i> exon 14 mutation: a research reportKatherine G Roth, Isa Mambetsariev, Ravi Salgia
Anticancer Research|August 21, 2003
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumorsEvan Pisick, Arthur T Skarin, Ravi Salgia
Cytokine & Growth Factor Reviews|November 25, 2004
The role of ephrins and Eph receptors in cancerHanna Surawska, Patrick C Ma, Ravi Salgia
Pageof 53

Showing results (51-60 of 528) with videos related to

Sort By:
Pageof 53
Iscience|July 6, 2023
Intrinsically disordered proteins and conformational noise: The hypothesis a decade laterPrakash Kulkarni, Ravi Salgia, Govindan Rangarajan
BMC Cancer|August 3, 2016
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgia
Reviews on Recent Clinical Trials|May 14, 2008
Review of clinic trials: agents targeting c-MetOyewale Abidoye, Nadh Murukurthy, Ravi Salgia
Thescientificworldjournal|September 7, 2004
Receptor tyrosine kinases and inhibitors in lung cancerEvan Pisick, Simha Jagadeesh, Ravi Salgia
Thescientificworldjournal|October 7, 2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLCMartin Sattler, Oyewale Abidoye, Ravi Salgia
Molecular Therapy Oncolytics|April 13, 2019
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1<sup>st</sup>-Line Treatment for Non-Small-Cell Lung CancerChongkai Wang, Prakash Kulkarni, Ravi Salgia
Expert Opinion on Drug Safety|February 10, 2015
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patientsAlana Dikopf, Kevin Wood, Ravi Salgia
Cold Spring Harbor Molecular Case Studies|December 18, 2020
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring <i>MET</i> exon 14 mutation: a research reportKatherine G Roth, Isa Mambetsariev, Ravi Salgia
Anticancer Research|August 21, 2003
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumorsEvan Pisick, Arthur T Skarin, Ravi Salgia
Cytokine & Growth Factor Reviews|November 25, 2004
The role of ephrins and Eph receptors in cancerHanna Surawska, Patrick C Ma, Ravi Salgia
Pageof 53